I arrived in Brazil, on Wednesday (20), for the brand 50% of the Brazilian population is fully immunized Two doses or one dose of vaccines against COVID-19. The number is optimistic, but it shows that we are still halfway there.
Many people are still resistant to vaccination A large part of this group uses as a basis for this decision false information transmitted by social networks. There are also those who opt for vaccinations and still don’t get what they want.
Thinking about quantifying these people, Data Science Consulting Ilumeo and the Brazilian Society of Virology (SBV) held a Search for marking What preferences and traits are most influential at the time of immunization.
The survey showed that 8 out of 10 participants would not refuse any vaccine, although one or the other may be preferred. actually 42% of 25-34-year-olds are the most likely to refuse the Covid-19 vaccine.
Among those interviewed, 4% said they would not be vaccinated. Distrust and fear are the main arguments cited and it is clear that fake news and a fundamental lack of knowledge about how vaccines work influence opinion.
Among those who do not intend to vaccinate, we see more men (53%) from the southeast (38%), with lower monthly household income and less education. When considering only people aged 45-54, the rate drops to 7%.
Despite being the first brands that touched the minds of respondents (36% and 30%, respectively), CoronaVac and AstraZeneca are the most rejected vaccines By the group the researchers heard.
The Chinese Sinovac vaccine, made by the Butantan Institute in Brazil, is at the forefront of rejections, with 15% lower preference and 7% more rejection, followed by AstraZeneca vaccine with 19% lower preference and 4% rejection.
CoronaVac has little confidence as it is seen as a less effective immunizing device compared to the others. However, it has been proven that The Chinese vaccine protects like others and prevents deaths from disease. The fear of AstraZeneca is due to the rare side effects.
Immunization devices from Pfizer and Janssen dominate the preference for Brazilians, with 17% approval and only 1% disapproval each. It is well accepted in Brazil for use in countries like the United States, and in Janssen’s case, for being a single dose.
In all, 3059 respondents were interviewed, and 51% had taken at least one dose of the vaccine. 48% are Class C, followed by 29% Class D and E and 21% are Class B. With regard to region, 40% are from the Southeast, 29% from the Northeast and 14% from the South.
And you, have you completed your Covid-19 vaccination? Tell us in the comments below!
“Writer. Analyst. Avid travel maven. Devoted twitter guru. Unapologetic pop culture expert. General zombie enthusiast.”